High-flow Nasal Oxygen Therapy for Hypoxia

This trial tests whether high-flow nasal oxygen therapy can maintain stable oxygen levels during an upper GI endoscopy. Sedation for this procedure often causes a drop in blood oxygen, which this therapy aims to prevent. Participants will receive either the standard oxygen treatment or high-flow nasal oxygen therapy to determine which is more effective. Individuals with sleep apnea, high BMI (body mass index), or low baseline oxygen levels may be suitable candidates for this trial. As an unphased trial, it offers participants the chance to contribute to valuable research that could enhance procedural safety for many patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that High-flow Nasal Oxygen Therapy (HFNO) is generally safe for people. Studies have found that patients using HFNO experience better breathing and higher oxygen levels. For instance, a review of several studies found that HFNO increased blood oxygen levels by an average of 57 mm Hg, indicating improved oxygenation.

Additionally, HFNO often provides more comfort compared to other oxygen delivery methods. While minor side effects like a dry nose or slight discomfort may occur, serious problems are rare. This treatment has been safely used in various situations, including for patients with severe breathing issues.

Researchers are excited about High-flow Nasal Oxygen Therapy (HFNO) for hypoxia because it offers a unique approach compared to standard oxygen therapy methods. Unlike traditional low-flow oxygen delivery, HFNO provides a higher flow of oxygen, which can better meet the body's demands and improve oxygenation more effectively. This method is also more comfortable for patients, as it delivers warm, humidified air, reducing the irritation often caused by conventional oxygen masks. Additionally, HFNO can be used continuously during various medical procedures, potentially reducing the risk of hypoxia in critical situations.

Research has shown that high-flow nasal oxygen therapy (HFNO), which participants in this trial may receive, can assist people with breathing problems. Studies have found that HFNO improves oxygen levels and eases breathing. It has been linked to better survival rates in severe cases. In one study, HFNO reduced death rates from 23% and 28% to just 12%. Additionally, HFNO provides warm and moist oxygen, making breathing more comfortable.²³⁶⁷⁸